Cytokinetics Ispinesib Could Help Fill Gap In HER2 Negative Breast Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cytokinetics is casting a wider net with its development program for ispinesib following the targeted oncologic’s failure earlier this year in a Phase II lung cancer trial.